Diaclide

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Diaclide

What is Diaclide? Overview and Identity

Property Description
Active ingredient Gliclazide
Form Tablet (Oral formulation)
Pharmacological class Oral Antidiabetic Agent (Second-Generation Sulfonylurea)
Common use Reduction of Blood Glucose Concentration
Origin Synthetic Compound (Benzene-sulfonylurea derivative)

What Type of Medicine is Diaclide? (Identity and Classification)

Diaclide is a proprietary pharmaceutical product used for managing elevated blood sugar, with the sole active ingredient being Gliclazide. It is formally classified as an oral antidiabetic agent, belonging to the sulfonylurea class of drugs. The active substance, Gliclazide, is a synthetic compound derived from Benzene-sulfonylurea and is clinically recognized as a second-generation sulfonylurea based on its pharmacological profile. Diaclide is strictly a single-ingredient product, formulated as a tablet for oral administration, ensuring a systemic therapeutic effect.


Diaclide: Purpose and Physical Form (Function and Presentation)

The fundamental purpose of this medication is to assist adults with Type 2 diabetes mellitus in achieving effective glycemic control through the necessary reduction of blood glucose concentration. Its role is established in the management of hyperglycemia as a primary agent for controlling blood sugar levels. The drug is manufactured as a solid pharmaceutical preparation in the tablet dosage form. This oral formulation offers a convenient, non-injectable route of delivery for managing this chronic metabolic condition.


How Does Diaclide Generally Benefit Blood Sugar? (High-Level Action)

Diaclide generally benefits blood sugar by acting as an insulin secretagogue, meaning its core action is to promote the body's natural stimulation of insulin release from the pancreatic cells. This physiological action is directly responsible for the resulting antihyperglycemic effect. By enhancing the pancreas's ability to secrete insulin, the drug helps to interrupt the persistent state of hyperglycemia, thereby working toward the overall goal of maintaining a controlled blood sugar balance.

Regulatory References

  1. sulfonylurea
  2. hyperglycemia
  3. insulin secretagogue

What side effects are possible with Diaclide?

Possible Side Effects and Safety Information

Diaclide (Gliclazide) is a medication used to treat type 2 diabetes and, like all medicines, it can cause side effects. It is vital to maintain regular monitoring of blood sugar levels and adhere to a strict diet and exercise plan as advised by your healthcare provider.


Common Side Effects

The most frequent and significant adverse reaction associated with Diaclide is hypoglycemia (low blood sugar). This occurs when blood glucose levels drop too low, and it may be more likely if meals are skipped, carbohydrate intake is insufficient, or alcohol is consumed.

Symptoms of hypoglycemia include, but are not limited to, sweating, intense hunger, confusion, trembling, fast heartbeat, dizziness, and headache. Always carry a quick source of sugar (such as glucose tablets or fruit juice) to treat symptoms immediately.

Other common side effects may include:

  • Gastrointestinal disturbances (e.g., abdominal pain, nausea, vomiting, diarrhea, or constipation)
  • Headache
  • Weight gain

These gastrointestinal effects are often minimized by taking the tablet with food, particularly breakfast.


Serious and Rare Side Effects

Rarely, Diaclide may cause serious adverse effects, including blood disorders (e.g., decreased blood cell counts, which can lead to fever, sore throat, or unusual bleeding) and liver problems (e.g., hepatitis, jaundice). Severe skin reactions, such as blistering or peeling of the skin, have also been reported. If you experience yellowing of the skin or eyes, unexplained bruising, or a severe rash, seek immediate medical attention.


Contraindications and Precautions

Diaclide is not recommended for use in patients with type 1 diabetes, diabetic ketoacidosis, or severe kidney or liver disease. It is also generally not advised for use during pregnancy or breastfeeding.

Alcohol consumption should be avoided as it increases the risk of severe hypoglycemia. Caution should be exercised when driving or operating machinery, especially at the start of treatment, until you know how the medication affects your blood sugar and concentration. Always inform your doctor of any existing medical conditions or other medications you are taking, as drug interactions can alter its effectiveness or increase side effect risks.

Overdose and Emergency Response

Overdose Manifestations

Overdose of Diaclide, which contains the active ingredient Gliclazide, is documented in official regulatory labeling as leading primarily to hypoglycemia (abnormally low blood glucose). The clinical presentation reflects the severity of this metabolic condition, ranging from moderate signs such as headache, intense hunger, sweating, tremor, and anxiety, to more serious neurological manifestations.

Severe Outcomes and Emergency Action

Severe and prolonged hypoglycaemia is the principal life-threatening outcome noted in product information, potentially resulting in loss of consciousness, convulsions, or coma. Regulatory guidance strictly mandates that immediate medical treatment and hospitalisation are required for any severe reaction. This urgent action must be sought even if a severe episode is temporarily managed with oral sugar intake.

Supportive Management and Monitoring

Management is defined as symptomatic and supportive, involving the administration of glucose (oral or intravenous). Due to the potential for relapse, official documents stipulate that careful hospital monitoring and continued glucose administration may be necessary for several days. Specific populations, including the elderly and those with hepatic or renal impairment, are noted to be particularly susceptible to severe, prolonged reactions.

Therapeutic Uses of Diaclide

What Diaclide Treats: Main Uses and Benefits

Diaclide is generally considered relevant for use across domains where additional symptomatic support is needed, specifically applied in conditions characterized by systemic imbalance. Its primary therapeutic area involves the management of Type 2 diabetes mellitus. It helps address symptom clusters associated with this condition, particularly during acute or unstable symptom patterns related to systemic imbalance. The medication assists with maintaining functional stability and supports the patient during episodes of heightened discomfort.

Quick Fact: Relevant for Symptoms of Systemic Imbalance

Diaclide may be part of symptomatic management, applied across domains where short-term symptomatic assistance is needed.


The medication is commonly used to help with symptoms that create noticeable functional strain, such as those that appear suddenly or fluctuate. It contributes to easing the overall symptom load and helps patients cope more steadily with symptom fluctuations.

“Diaclide is relevant when supportive symptom management is appropriate and contributes to improved comfort during periods of heightened symptoms.”

Regulatory References

  1. HPRA official document for Diaclide MR

Eligibility and Restrictions for Use

Who Can and Cannot Use Diaclide?

Eligibility for Diaclide (Gliclazide) is strictly defined by regulatory guidelines, focusing on specific patient populations and conditions. This medication is officially designated for use by adults (18 years of age and older) diagnosed with Type 2 diabetes mellitus.


Contraindicated Populations

Use of Diaclide is absolutely contraindicated by regulatory labeling in several key populations:

  • Patients with Type 1 diabetes mellitus or acute states like diabetic ketoacidosis.
  • Patients with severe hepatic or severe renal impairment.
  • Individuals with known hypersensitivity to Gliclazide, other sulfonylureas, or sulfonamides.
  • Pregnant and breastfeeding women.

Age-Related and Conditional Restrictions

Age Group / Condition Regulatory Status
Children/Adolescents (Under 18) Not recommended; safety/efficacy not established.
Concomitant Miconazole Contraindicated (Systemic or oromucosal).
Mild to Moderate Renal Impairment Conditional use; requires close monitoring.

Eligibility is contingent upon not having these contraindications, as the medicine is not suitable for these groups.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Diaclide (Gliclazide) is structured around the risk of altering blood glucose control through both pharmacodynamic and pharmacokinetic mechanisms.

Interaction-Related Restrictions

Co-administration with Miconazole (systemic or oromucosal gel) is formally contraindicated due to the risk of significant potentiation of the hypoglycemic effect. The consumption of alcohol is also restricted, as it potentiates the hypoglycemic reaction, which can progress to coma.


Pharmacodynamic and Metabolic Interactions

Interaction Type Interacting Substances/Classes
Potentiation of Hypoglycemia Other antidiabetic agents, ACE Inhibitors, NSAIDs, Beta-blockers
Antagonism (Hyperglycemic Effect) Corticosteroids, Danazol, Chlorpromazine
Exposure Increase (CYP2C9) Inhibitors like Fluconazole (increase Gliclazide plasma concentration)

Pharmacodynamic potentiation involves additive or synergistic effects with other agents that lower blood glucose, while antagonism involves agents with intrinsic hyperglycemic properties that reduce the antidiabetic effect. Furthermore, CYP2C9 inhibitors increase Diaclide's plasma concentration by reducing its clearance, thereby elevating the risk of hypoglycemia. Interaction risks are noted as greater in patients with severe hepatic or renal impairment.

Mechanism of Action

Diaclide's primary mechanism of action is the stimulation of insulin release from the pancreatic beta-cells. The drug acts as an insulin secretagogue by targeting the sulfonylurea receptor 1 (SUR1) subunit, which is an integral component of the ATP-sensitive potassium ( K ATP) channel complex on the beta-cell membrane.

Diaclide functions as an inhibitor by binding to SUR1. This binding closes the K ATP channel, preventing the efflux of potassium ions ( K^+) from the cell. The subsequent accumulation of K^+ ions leads to the depolarization of the beta-cell membrane. This change in membrane potential triggers the opening of voltage-dependent calcium channels ( Ca^2+). The rapid influx of extracellular Ca^2+ ions initiates the cascade for exocytosis, resulting in an enhanced release of insulin into the systemic circulation. The resulting increase in circulating insulin modulates systemic glucose homeostasis.

Dosage and Administration Information

Diaclide (Gliclazide) is strictly administered via the oral route as a tablet formulation. Its usage is governed by distinct regimens for the Immediate-Release (IR) and Modified-Release (MR) forms, both of which require timing the intake with a meal, specifically with breakfast or the first main meal of the day.

For the MR formulation, the starting daily dose is 30 mg, taken once daily, which may be titrated up to a maximum daily dose of 120 mg. A critical administration rule for the MR tablet is that it must be swallowed whole and cannot be crushed, chewed, or divided, as this would compromise its modified-release properties.

In contrast, the IR tablets begin at 40 mg to 80 mg daily and can be titrated up to a maximum of 320 mg. While doses up to 160 mg may be taken as a single morning dose, any total dose exceeding 160 mg daily must be distributed into divided doses (twice daily).

Regarding specific populations, the standard adult regimen is applicable for both older adults (ge 65 years) and patients with mild to moderate renal impairment, though use is not authorized for pediatric patients. If a dose is forgotten, the standard procedure is to skip the missed dose and take the next dose at the usual time; the next dose must not be doubled.

Recent Clinical Evidence

Evidence for Use in Type 2 Diabetes Mellitus

Diaclide (Gliclazide) was studied to explore its effect on high blood glucose concentration in adults with Type 2 Diabetes Mellitus. Researchers primarily used Randomized Controlled Trials (RCTs) and Systematic Reviews to assess initial observations and compare the medication against other treatments or a placebo. These studies examined changes in key biomarkers, most notably Glycosylated Hemoglobin (HbA1c), a common measure of long-term blood sugar control. Findings describe patterns observed where changes in HbA1c levels were measured in participants using Diaclide. Comparative studies explored outcomes related to systemic imbalance, with patterns of change varying depending on the specific comparator used.

Long-Term Evidence and Durability of Study Findings

To understand the patterns of long-term observation, large-scale outcome trials and observational studies were conducted over extended periods, sometimes lasting five years or more. These studies explored outcomes linked to physiological strain and focused on major events. Researchers examined the incidence of major macrovascular and microvascular events, such as heart attack or stroke, during the long period of observation. It is important to note that long-term effects are not fully established based solely on single, dedicated RCTs for some outcomes. The information available often comes from secondary analyses of large-scale trials or from observational settings.

Evidence in Special Populations and Research Gaps

Diaclide was evaluated in research involving specific patient groups beyond the general adult population, including the elderly and those with renal impairment (kidney issues). Data show patterns related to use in these groups, though subgroup findings are uncertain or data for certain groups remain insufficient. Follow-up durations were limited in many comparative trials. Evidence quality varies across studies, and limited information for long-term outcomes is available from trials specifically designed for those endpoints. Research provides context but not individual predictions about how any person might respond.

Key Studies & References

  1. HPRA official document for Diaclide MR (Gliclazide Product Information)

Frequently Asked Questions (FAQ)

Common questions about Diaclide (FAQ)


Q: Is Diaclide considered a first-line medication for Type 2 diabetes?

Regulatory references and national health guidelines often classify Gliclazide (the active ingredient in Diaclide) as an agent used when treatment goals are not met with initial therapies, or when those therapies are unsuitable. It is designated for use as a primary agent in achieving glycemic control.


Q: How long does it typically take for Diaclide to start working?

Official product information on Diaclide's pharmacokinetics describes how the drug is absorbed after administration. The concentration of the drug in the blood typically reaches its maximum level between two and six hours, or over a longer plateau of 6 to 12 hours for the Modified-Release formulation. This process is when the drug begins its pharmacological effect in the body.


Q: Can herbal supplements or vitamins affect how Diaclide works?

Diaclide is metabolized extensively in the liver, and co-administration with other products, including some herbal supplements or high-dose vitamins, can potentially alter its effects. This may increase the risk of low blood sugar (hypoglycemia). For this reason, it is important to inform your healthcare provider of all supplements you are currently taking, as noted in official safety information.


Q: Are there specific foods I should avoid while on Diaclide?

While the medicine must be taken with a meal to minimize the risk of low blood sugar, official guidelines primarily emphasize the importance of adhering to a strict diet plan advised by your doctor. The consumption of alcohol is specifically restricted in regulatory documents because it is known to significantly increase the risk of a severe hypoglycemic reaction.


Q: Can Diaclide cause long-term damage to organs like the pancreas or kidneys?

Diaclide is a long-term treatment for Type 2 diabetes. Regulatory documentation states the medicine is contraindicated (not recommended) if you already have severe kidney or liver disease. Official safety documents do not contain statements indicating that the medicine itself causes long-term damage to the pancreas or kidneys, though its use is restricted in cases of pre-existing severe kidney or liver disease.


Q: Can Diaclide affect my energy levels during the day?

Official product information notes that the most frequent side effect, hypoglycemia (low blood sugar), can cause symptoms related to low energy. These effects may include drowsiness, a feeling of unusual weakness, or general lack of energy. These symptoms usually resolve once blood sugar is stabilized.


Q: Does Diaclide make the skin more sensitive to sunlight?

Some consumer information and post-marketing reports have indicated that increased skin sensitivity to the sun, known as photosensitivity, is a possible effect for some individuals using Gliclazide. This possible effect may indicate a need for caution with sun exposure.


Q: If my blood sugar levels are controlled, can I stop taking Diaclide?

Regulatory guidelines state that treatment for Type 2 diabetes is generally continuous. Abruptly discontinuing the medication can lead to a loss of blood sugar control, and cessation must be determined by a physician. Official documents state that stopping treatment must be guided by your healthcare provider.


Q: Is it normal to feel less hungry when first starting Diaclide?

While one of the main symptoms of low blood sugar (hypoglycemia) is often intense hunger, Diaclide can also commonly cause gastrointestinal disturbances, such as nausea or abdominal pain. These side effects, which official documents recommend minimizing by taking the tablet with food, may lead to a reduced appetite.


Q: Is Diaclide known to affect cholesterol levels?

Studies cited within regulatory documentation have reported that Gliclazide is associated with observations of reduced plasma levels of cholesterol and triglycerides in some individuals after continued use. This observation is part of its wider metabolic profile.


Q: Can Diaclide cause vision changes, like blurred vision?

Official product information lists blurred vision as a potential symptom of a significant drop in blood sugar, or hypoglycemia. Additionally, rapid changes in blood sugar levels at the start of any diabetes treatment may temporarily affect your vision, though this effect is generally short-lived.


Q: Can stress or illness affect my blood sugar while taking Diaclide?

Yes, official warnings in regulatory documentation caution that it may be harder to maintain blood sugar control during times of physical or emotional stress. This includes situations like developing a fever, having an infection, sustaining an injury, or undergoing surgery. Official warnings note that if you become ill, consultation with your healthcare provider is required.


Q: Is it normal for my blood sugar to still fluctuate after starting Diaclide?

Diaclide is prescribed to achieve and maintain improved glycemic control (blood sugar balance) by lowering high blood glucose concentrations. While the goal is better control, the official regulatory documents acknowledge that blood sugar levels are naturally influenced by many factors, including diet, activity, and stress, which can still cause fluctuations.

How should Diaclide be stored and disposed of?

How to Store and Dispose of Diaclide?

Official regulatory documents define strict rules for the storage and disposal of Diaclide (Gliclazide tablets).


Storage Requirements

Constraint Requirement
Temperature Store below 25 C or, regionally, below 30 C.
Protection Keep in a cool, dry place and protected from light.
Packaging Must remain in the original pack until the time of use.
Safety Keep out of the sight and reach of children and pets.

Disposal Instructions

Any unused or expired product must be discarded in accordance with local requirements. It is officially mandated that Diaclide must not be emptied into drains or otherwise released into the environment through household wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Diaclide found in:

A-Z Index: